Window of opportunity clinical trial designs to study cancer metabolism

Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 122; číslo 1; s. 45 - 51
Hlavní autoři:	Aroldi, Francesca, Lord, Simon R.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.01.2020 Nature Publishing Group
Témata:	631/154 631/67 631/67/2327 Antidiabetics Biological activity Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer therapies Clinical trials Clinical Trials as Topic - methods Drug development Drug metabolism Drug Repositioning - methods Drug Resistance Epidemiology Humans Metabolism Metabolomics Metformin Metformin - therapeutic use Mitochondria Molecular Medicine Neoplasms - drug therapy Neoplasms - metabolism Oncology Pharmacodynamics Research Design Review Review Article Time-to-Treatment Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Window of opportunity trials exploit the ‘window’ of time after cancer diagnosis, typically prior to initiation of cancer therapy. In recent years this study design has become a more regular feature of drug development, as this ‘window’ provides an opportunity to carry out a thorough pharmacodynamic assessment of a therapy of interest in tumours that are unperturbed by prior treatment. Many of the first window trials interrogated the bioactivity of drugs being repurposed for cancer treatment, in particular the anti-mitochondrial agent, metformin. In this review, we describe examples of window study designs that have been used to assess drugs that target cancer metabolism with a focus on metformin. In addition, we discuss how window studies may aid the development of molecular metabolic cancer imaging.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	0007-0920 1532-1827 1532-1827
DOI:	10.1038/s41416-019-0621-4